BETABiohacksAI is a research tool for informational purposes only. All outputs are computational hypothesis candidates — not confirmed mechanisms, not medical advice, and not a substitute for professional medical judgment. Independent experimental validation is always required.
BiohacksAI is an evolving scientific literature platform. New compounds and evidence are indexed continuously.
B

Rapamycin

A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.

490+ PubMed studies analyzed · 22 RCTs · Evidence Score: 55.6

Research Domains

Rapamycin has been studied across 22 research domains including ⏳ Longevity & Aging, 🔬 Oncology, 🛡️ Immunity, 🏋️ Muscle & Hypertrophy, 🫘 Kidney. The primary research focus is ⏳ Longevity & Aging with 37% of studies addressing this area.

Similar Compounds by Shared Targets

The following compounds share molecular targets with Rapamycin, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.

Everolimus
10 shared targets
ly294002
15 shared targets
sirolimus
9 shared targets
Wortmannin
11 shared targets
alpelisib
8 shared targets
torin
9 shared targets
tacrolimus
6 shared targets
pf
6 shared targets
buparlisib
6 shared targets
ly
7 shared targets
Loading evidence profile...

This evidence profile for Rapamycin is generated deterministically from 490 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.

Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.